Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK5 | Q00535 | 1/20 | 0.47 |
| ▸ | CDK5R1 | Q15078 | 1/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.45 |
| ▸ | EPHX2 | P34913 | 4/20 | 0.45 |
| ▸ | NAMPT | P43490 | 3/20 | 0.45 |
| ▸ | POLB | P06746 | 2/20 | 0.45 |
| ▸ | FLT3 | P36888 | 1/20 | 0.44 |
| ▸ | GRM5 | P41594 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 2/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | PIM1 | P11309 | 1/20 | 0.40 |
| ▸ | PIM2 | Q9P1W9 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3847010 | 0.92 | ALDH1A1 (0.46) | CDK5CDK5R1CYP2C9EPHX2NAMPT | |
| SCHEMBL4491359 | 0.91 | POLB (0.45) | CDK5CDK5R1CYP2C9EPHX2NAMPT | |
| SCHEMBL4491364 | 0.91 | POLB (0.45) | CDK5CDK5R1CYP2C9EPHX2NAMPT | |
| SCHEMBL4501781 | 0.91 | EPHX2 (0.53) | CDK5CDK5R1CYP2C9EPHX2NAMPT | |
| SCHEMBL4501778 | 0.91 | EPHX2 (0.53) | CDK5CDK5R1CYP2C9EPHX2NAMPT | |
| SCHEMBL4504619 | 0.91 | PIM1 (0.47) | CDK5CDK5R1CYP2C9EPHX2NAMPT | |
| SCHEMBL4504622 | 0.91 | PIM1 (0.47) | CDK5CDK5R1CYP2C9EPHX2NAMPT | |
| SCHEMBL5271176 | 0.90 | HPGD (0.46) | NAMPTFLT3GRM5HPGDNPC1 | |
| SCHEMBL3847391 | 0.89 | CCNC (0.49) | EPHX2NAMPTPOLBFLT3 | |
| SCHEMBL2569893 | 0.89 | CDK5 (0.43) | CDK5CDK5R1CYP2C9EPHX2NAMPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1830842-B1 | MEDICAMENTS FOR THE TREATMENT OR PREVENTION OF FIBROTIC DISEASES | BOEHRINGER INGELHEIM INT (DE) | 2009-04-22 | — | — | EP | claimed |
| EP-1830842-B1 | MEDICAMENTS FOR THE TREATMENT OR PREVENTION OF FIBROTIC DISEASES | BOEHRINGER INGELHEIM INT (DE) | 2009-04-22 | — | — | EP | disclosed |
| US-20090048267-A1 | MEDICAMENTS FOR THE TREATMENT OR PREVENTION OF FIBROTIC DISEASES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-02-19 | — | — | US | disclosed |
| EP-1830842-A1 | MEDICAMENTS FOR THE TREATMENT OR PREVENTION OF FIBROTIC DISEASES | Boehringer Ingelheim International GmbH (DE) | 2007-09-12 | — | — | EP | disclosed |
| US-20060154939-A1 | Medicaments for the Treatment or Prevention of Fibrotic Diseases | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2006-07-13 | — | — | US | disclosed |
| WO-2006067168-A1 | MEDICAMENTS FOR THE TREATMENT OR PREVENTION OF FIBROTIC DISEASES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2006-06-29 | — | — | WO | disclosed |
| US-6858641-B2 | Substituted indolinones | BOEHRINGER INGELHEIM PHARMA KG (DE) | 2005-02-22 | — | — | US | disclosed |
| US-20030092756-A1 | Substituted indolinones | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2003-05-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030092756-A1 | Substituted indolinones | CDK1, CDK2, CDKL1 | CDK5 19/4885CDK5R1 32/4885CYP2C9 423/4885 |
| US-20060154939-A1 | Medicaments for the Treatment or Prevention of Fibrotic Diseases | MMP1, COL1A1, FOXM1 | CDK5 990/4885CDK5R1 701/4885CYP2C9 2022/4885 |
| US-20090048267-A1 | MEDICAMENTS FOR THE TREATMENT OR PREVENTION OF FIBROTIC DISEASES | COL1A1, MMP1, FOXM1 | CDK5 1011/4885CDK5R1 558/4885CYP2C9 2084/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.